



PHARMACOECONOMICS: A COMPREHENSIVE REVIEW OF METHODOLOGIES, APPLICATIONS, AND ITS EVOLVING ROLE IN GLOBAL AND INDIAN HEALTHCARE SYSTEMS

Panchal Lesha^{1*}, Vivek Pitroda², Ashutosh Chourishi³

¹*,²PG student, Department of Pharmacology, Government Medical College, Shivpuri, MP, India.

³Department of Pharmacology, Government Medical College, Shivpuri, MP, India.

Corresponding Author: Panchal Lesha, Department of Pharmacology, Government Medical College, Shivpuri, MP, India.

Email: ¹*pgpharmac@gmail.com

ABSTRACT

As modern healthcare systems encounter an era of unprecedented technological advancement alongside escalating costs, the discipline of pharmacoeconomics has become an essential pillar for sustainable policy and practice. Pharmacoeconomics, a specialized branch of health economics, provides a structured framework to evaluate the value of pharmaceutical products and services by meticulously balancing their costs against their clinical and humanistic benefits. This review explores the fundamental methodologies of pharmacoeconomic analysis—including Cost-Effectiveness, Cost-Minimization, Cost-Utility, and Cost-Benefit analyses—and examines their application across various disease states such as hypertension, diabetes, and rheumatoid arthritis. Special attention is given to the Indian healthcare landscape, where pharmacoeconomic data is increasingly integrated into national pricing policies and universal health coverage schemes like Ayushman Bharat. Despite challenges related to data infrastructure and the digital divide in low- and middle-income countries (LMICs), the integration of digital health data and artificial intelligence promises to refine these assessments for the future.

Keywords: Pharmacoeconomics, Indian Healthcare Landscape, Applications.

INTRODUCTION

The Global Imperative for Pharmacoeconomics:

The global pharmaceutical industry is witnessing a rapid influx of sophisticated and often expensive new treatments, primarily originating from industrialized nations such as the United States, Japan, and the United Kingdom. While these innovations offer hope for both communicable and non-communicable diseases, they also place immense strain on national healthcare budgets. Governments worldwide are currently grappling with the dual challenge of ensuring affordable access to medicine while maintaining the stability of the healthcare sector.

Several factors contribute to the rising trajectory of healthcare expenditures: increased life expectancy, higher standards of living, and an escalating demand for high-quality, technology-driven care. In many developing nations, pharmaceutical costs can account for as much as 30% to 40% of total healthcare spending, whereas in developed nations, this figure typically ranges between 10% and 15%.

Because medications represent a significant portion of the total cost of care, it is no longer sufficient to select therapies based solely on acquisition price; rather, decision-makers must consider the long-term economic impact, including potential cost savings from avoided hospitalizations and improved patient productivity [1-5].

Pharmacoeconomics serves as the vital bridge in this context, defining how to allocate limited health resources based on a trifecta of medicine safety, cost-benefit, and effectiveness. It allows pharmacy administrators and practitioners to make informed judgments, ensuring that the right patient receives the right medication at the right time while maintaining fiscal accountability [6].

The Indian Healthcare Landscape: A Strategic Perspective:

India occupies a unique and powerful position in the global pharmaceutical market. Often referred to as the "pharmacy of the world," India fulfills approximately 50% of the global demand for vaccines, 40% of generic demand in the US, and 25% of all medicines in the UK. Domestically, the sector is massive, comprising over 10,500 production units and 3,000 medicinal firms. The Indian pharmaceutical market, valued at roughly 42 billion in 2021, 120–130 billion by 2030 [7-8].

However, this manufacturing prowess coexists with significant challenges in domestic healthcare delivery. Approximately 60% of total health spending in India remains out-of-pocket, making



www.ajmrhs.com
eISSN: 2583-7761

Date of Received: 30-01-2025
Date Acceptance: 5-03-2026
Date of Publication: 11-03-2026

affordability a critical concern for the average citizen. In this price-sensitive environment, pharmacoeconomics is essential for.

- **Bridging the Gap:** Connecting India's massive generic manufacturing potential with the need for equitable and affordable healthcare access.
- **Policy Integration:** Assisting bodies like the National Pharmaceutical Pricing Authority (NPPA) in setting ceiling prices for essential medications.
- **Insurance Sustainability:** Informing the selection of Health Benefit Packages (HBPs) for government schemes to ensure long-term viability.

Methodologies of Pharmacoeconomic Analysis

To accurately determine the value of a drug, pharmacoeconomics utilizes four primary analytical frameworks. These methods vary based on how they measure outcomes and the specific clinical scenarios they address.

Cost-Effectiveness Analysis (CEA): CEA is the most common methodology used when comparing two or more treatment options that have varying levels of efficacy. It measures costs in monetary terms while expressing outcomes in natural clinical units, such as lives saved, illnesses cured, or blood pressure reduction in mmHg [9]

- **Incremental Cost-Effectiveness Ratio (ICER):** The core metric of CEA is the ICER, which represents the additional cost required to achieve one additional unit of health benefit. [10]

Formula: $ICER = \frac{\text{Cost Treatment 2} - \text{Cost Treatment 1}}{\text{Effectiveness Treatment 2} - \text{Effectiveness Treatment 1}}$

Cost-Minimization Analysis (CMA)

CMA is employed when the clinical outcomes of two or more therapies are proven to be therapeutically equivalent. Since the results are identical, the analysis focuses purely on identifying the least expensive option, including the costs of acquisition, preparation, and administration.

Primary Use: CMA is the standard tool for comparing branded drugs with their bioequivalent generics. [11]

Cost-Utility Analysis (CUA):

CUA is a sophisticated method that incorporates both the quality and quantity of life into a single metric. This is achieved through "health-adjusted life years," most commonly Quality-Adjusted Life Years (QALYs) or Disability-Adjusted Life Years (DALYs). [12,13]

Significance: By using QALYs, CUA allows for the comparison of treatments across completely different disease states (e.g., comparing a new cancer drug to a new diabetes treatment) based on the "utility" or value they provide to the patient's life.

Cost-Benefit Analysis (CBA)

In CBA, both the costs of an intervention and its resulting outcomes are expressed in **monetary terms**. This allows for a direct calculation of the net financial impact of a decision.

- **Application:** While useful for broad policy decisions (e.g., deciding whether to fund a new hospital versus a public health campaign), it is often more difficult to assign a monetary value to a human life or a year of health. [14]

Integration into Indian Healthcare Policy: India has made significant strides in institutionalizing pharmacoeconomics to manage its vast and diverse healthcare needs.

National Pharmaceutical Pricing Authority (NPPA): The NPPA, operating under the Drugs (Prices Control) Order (DPCO)-2013, uses pharmacoeconomic data to regulate the ceiling prices of over 800 formulations. When re-pricing life-saving medications like insulin or antihypertensives, the NPPA considers the "cost offsets"—the money saved by the health system through reduced hospital admissions—rather than just the purchase price of the pill [15].

Ayushman Bharat (PM-JAY): The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, which provides secondary and tertiary care to over 500 million beneficiaries, relies heavily on pharmacoeconomic evidence to update its Health Benefit Packages. By using cost-utility indicators like QALYs, the scheme prioritizes high-value interventions and cost-effective generics for chronic diseases. Pilot projects have indicated that this evidence-based approach can reduce avoidable spending by 15-20%, helping to limit catastrophic health expenditures for the poor.

Government Formularies (CGHS and ESIC): The Central Government Health Scheme (CGHS) and Employees State Insurance Corporation (ESIC) utilize cost-minimization studies to favor bioequivalent generics over expensive branded versions. It is estimated that this practice saves approximately 500-700 crore rupees annually across these programs. [16]

Disease-Specific

Applications:

Pharmacoeconomic principles are applied daily to optimize treatment protocols for both chronic and infectious diseases.

- **Allergy Management:** In treating Allergic Rhinitis, pharmacoeconomic studies help determine the best route for Allergen Immunotherapy (AIT). Comparisons between sublingual (SLIT) and subcutaneous (SCIT) therapy have shown SLIT to be more cost-effective when indirect costs, such as travel time and lost work, are factored into the equation.
- **Hypertension:** Studies in Indian tertiary care hospitals have demonstrated that amlodipine monotherapy is significantly more affordable than certain combination therapies, which is vital

for reducing the financial burden in a country with high out-of-pocket spending.

- **Diabetes:** For Type 2 Diabetes, newer classes like SGLT-2 inhibitors are being analyzed for their long-term value. While they may have higher acquisition costs than older drugs, their renal and cardiovascular benefits often make them cost-effective by preventing expensive long-term complications.

- **Rheumatoid Arthritis (RA):** To manage RA, healthcare facilities use ABC/VEN matrix analysis to prioritize "Vital" drugs in the inventory, ensuring that essential medications are always available while optimizing the budget. [18-19]

Implementation Challenges and Barriers: Despite its evident benefits, the implementation of pharmacoeconomics, particularly in LMICs, faces several hurdles:

- **Data Deficits:** Many developing nations lack the robust, transparent infrastructure required to collect consistent data on medication consumption, safety, and real-world costs.
- **The Digital Divide:** While digital health is a burgeoning field, in many LMICs, only **one out of four people** have access to the internet, making it difficult to collect comprehensive digital health endpoints.
- **Human Resources:** There is a critical shortage of trained personnel. The field would benefit greatly from the increased involvement of clinical pharmacists and PharmD **graduates** who are trained to apply economic principles to clinical practice.
- **Rationing Dilemmas:** Value-based rationing creates ethical challenges, as governments must sometimes decide whether to fund life-saving "vital" drugs (like adrenaline) over treatments that "only" improves quality of life (like those for lifestyle conditions).[20]

The Future: Digital Health and AI: The future of pharmacoeconomics lies in moving away from hypothetical models toward **real-world evidence**.

- **Ayushman Bharat Digital Mission (ABDM) :** Since its launch, the ABDM has created over **450 million health accounts**, providing a massive database of real-world outcomes that can be linked to electronic health records.[16]
- **Artificial Intelligence (AI):** AI is being integrated into Health Technology Assessment (HTA) frameworks to improve the modeling of chronic diseases like epilepsy, allowing for more precise cost-effectiveness predictions.
- **Shift in Assessment:** Future appraisals will likely focus on actual adoption rates and real cost offsets within the health system rather than outcomes achieved under "perfect" clinical trial conditions.

CONCLUSION

Pharmacoeconomics is no longer an optional academic exercise; it is an indispensable tool for the survival of modern healthcare systems. By providing a structured, evidence-based approach to resource allocation, it ensures that limited financial resources are directed toward the most effective and safe therapies. For a country like India, which serves as a global generic powerhouse, the maturation of pharmacoeconomic practice is essential to balance industrial growth with the moral imperative of providing equitable, affordable, and high-quality care to its vast population. Continued investment in education, legislative frameworks, and digital infrastructure will be the key to unlocking the full potential of this discipline in the years to come.

Source of Support: Nil, Conflicts of Interest: None declared.

REFERENCES

1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the economic evaluation of health care programmes*. 4th ed. Oxford: Oxford University Press; 2015.
2. Bootman JL, Townsend RJ, McGhan WF. *Principles of pharmacoeconomics*. 3rd ed. Cincinnati: Harvey Whitney Books; 2005.
3. Rascati KL. *Essentials of pharmacoeconomics*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
4. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. *Cost-effectiveness in health and medicine*. 2nd ed. Oxford: Oxford University Press; 2017.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. *Cost-effectiveness in health and medicine*. New York: Oxford University Press; 1996.
6. Briggs AH, Claxton K, Sculpher MJ. *Decision modelling for health economic evaluation*. Oxford: Oxford University Press; 2006.
7. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. *N Engl J Med*. 1977;296(13):716-21.
8. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? *Med Decis Making*. 2001;21(4):329-34.
9. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments for resource

- allocation decisions. *Int J Technol Assess Health Care*. 2008;24(3):244-58.
10. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. *BMJ*. 2013;346:f1049.
 11. World Health Organization. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
 12. Prinja S, Downey LE, Gauba VK, Swaminathan S. Health technology assessment for policy making in India: current scenario and way forward. *Pharmacoeconomics*. 2018;36(3):255-63.
 13. Prinja S, Bahuguna P, Gupta I, Chowdhury S, Trivedi M. Role of health technology assessment in strengthening health systems in India. *Natl Med J India*. 2020;33(3):165-70.
 14. Government of India. National Health Policy 2017. New Delhi: Ministry of Health and Family Welfare; 2017.
 15. National Pharmaceutical Pricing Authority. Drugs (Prices Control) Order 2013. New Delhi: Government of India; 2013.
 16. Ministry of Health and Family Welfare. Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana: operational guidelines. New Delhi: Government of India; 2018.
 17. World Health Organization. Global spending on health: weathering the storm. Geneva: WHO; 2020.
 18. OECD. Health at a glance 2023: OECD indicators. Paris: Organisation for Economic Co-operation and Development; 2023.
 19. Gupta I, Prinja S. Health economics and pharmacoeconomics in India: issues and challenges. *Pharmacoeconomics*. 2016;34(6):521-5.
 20. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the \$50,000-per-QALY threshold. *N Engl J Med*. 2014;371(9):796-7

How to cite this article: Panchal Lesha, Vivek Pitroda, Ashutosh Chourishi, PHARMACOECONOMICS: A COMPREHENSIVE REVIEW OF METHODOLOGIES, APPLICATIONS, AND ITS EVOLVING ROLE IN GLOBAL AND INDIAN HEALTHCARE SYSTEMS, *Asian J. Med. Res. Health Sci.*, 2026; 4 (1):654-657.
Source of Support: Nil, Conflicts of Interest: None declared.